Psilocybin for Depression With Loss of Interest or Pleasure
Treatments studied
Part of Brain & nervous system clinical trials.
This study tests whether psilocybin, a naturally occurring psychedelic compound, can help people with depression who experience anhedonia—a loss of interest or pleasure in activities. Researchers will monitor your brain activity and mood changes over time to see if this treatment is safe and helpful.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 18 and 65 years old
- Have major depressive disorder with significant anhedonia (loss of interest or pleasure in things)
- Have not used psilocybin, LSD, or similar psychedelics in the past year
- Have a trusted support person who can help during the study
- Be willing to stop all supplements and over-the-counter medications for at least one week before treatment
- Not be pregnant, planning to become pregnant, or nursing during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if psilocybin, a psychedelic substance, can improve the ability to feel pleasure (anhedonia) in people with depression who are not taking antidepressants. It also includes healthy volunteers as a comparison group.
This trial tests if psilocybin, a substance found in certain mushrooms, can help people with various mental health symptoms that affect daily life. You would take a single dose in a supervised setting and be monitored for changes in your mood and well-being.
This study tests whether combining psilocybin (a psychedelic substance) with pimavanserin (a medication that may help reduce side effects) works better than psilocybin alone for treating major depressive disorder. It may help people who have not responded well to other treatments.
This trial tests whether a single dose of psilocybin can help people with treatment-resistant depression by changing how they focus on themselves. It aims to understand how psilocybin affects brain activity and self-related thinking.
This study tests whether a single dose of psilocybin (a psychedelic compound) can help treat depression by looking at brain changes on MRI. It is designed for people with moderate-to-severe depression who have not responded well to other treatments.
This study tests if psilocybin (a psychedelic) combined with cognitive behavioral therapy (CBT) can help people with major depression. You would receive the psilocybin in a supervised setting and have talk therapy before and after.
Hear when a new Anhedonia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.